From the Department of Orthopaedic Surgery, Medical University of South Carolina, Charleston, South Carolina.
J Am Acad Orthop Surg. 2022 Aug 15;30(16):789-797. doi: 10.5435/JAAOS-D-21-01064.
The purpose of this study was to determine whether total ankle arthroplasty (TAA) and ankle/hindfoot fusion patients receiving tranexamic acid (TXA) exhibit fewer wound complications.
A retrospective review was conducted of 212 patients (217 feet) undergoing TAA (n = 72), ankle (n = 36), tibiotalocalcaneal (n = 20), pantalar (n = 1), or hindfoot fusion (ie, subtalar = 47, double = 33, and triple = 8) between 2015 and 2020 by a fellowship-trained foot and ankle surgeon at an academic medical center. Demographics, medical history, complications, and union status were compared between TXA (n = 101) and non-TXA (n = 116) cohorts. The mean follow-up was 1.24 years (range, 0.25 to 4.68).
The TXA group had significantly less postoperative infections (5.9% versus 15.5%, P = 0.025). Within a subgroup analysis of ankle/hindfoot fusions, the TXA group exhibited significantly more Charcot neuroarthropathy (20.7% versus 5.7%, P = 0.006) and shorter follow-up duration (0.96 versus 1.30 years, P = 0.030); however, TXA was associated with shorter time to fusion (146 versus 202 days, P = 0.049) and fewer revision surgeries (8.6% versus 21.8%, P = 0.036). Subgroup analysis excluding feet with Charcot also demonstrated less postoperative infections (4.5% versus 14.4%, P = 0.020). Subgroup analysis of TAAs showed fewer cases of superficial infections (2.3% versus 27.6%, P = 0.002) and delayed wound healing (25.6% versus 48.3%, P = 0.047) in the TXA cohort.
TXA use in ankle/hindfoot surgery was correlated with a reduction in superficial infections and radiographic time to union. The use of TXA in TAA correlated with fewer superficial infections and cases of delayed wound healing. Thus, in addition to other areas of orthopaedics, TXA seems to be beneficial in hindfoot and ankle surgery.
All data were obtained from our institution's medical records. This study is not associated with a clinical trial.
本研究旨在确定全踝关节置换术(TAA)和踝关节/后足融合患者使用氨甲环酸(TXA)是否会减少伤口并发症。
对 2015 年至 2020 年间,一名在学术医疗中心接受足部和踝关节 fellowship培训的外科医生对 212 名患者(217 只脚)进行了回顾性研究,包括 TAA(n=72)、踝关节(n=36)、胫距跟(n=20)、距下(n=1)或后足融合(即距下=47,双距下=33,三距下=8)。比较 TXA 组(n=101)和非 TXA 组(n=116)患者的人口统计学、病史、并发症和融合状态。平均随访时间为 1.24 年(0.25 至 4.68 年)。
TXA 组术后感染发生率明显较低(5.9%比 15.5%,P=0.025)。在后足融合亚组分析中,TXA 组 Charcot 神经关节病的发生率明显较高(20.7%比 5.7%,P=0.006),随访时间明显较短(0.96 年比 1.30 年,P=0.030);然而,TXA 与融合时间更短(146 天比 202 天,P=0.049)和更少的翻修手术(8.6%比 21.8%,P=0.036)相关。排除 Charcot 足部的亚组分析也显示术后感染发生率较低(4.5%比 14.4%,P=0.020)。TAA 亚组分析显示,TXA 组浅表感染(2.3%比 27.6%,P=0.002)和伤口愈合延迟(25.6%比 48.3%,P=0.047)的发生率较低。
在后足和踝关节手术中使用 TXA 与减少浅表感染和放射学愈合时间相关。TAA 中 TXA 的使用与较少的浅表感染和伤口愈合延迟病例相关。因此,除了矫形外科的其他领域外,TXA 似乎在后足和踝关节手术中也有益。
所有数据均来自我们机构的病历。本研究与临床试验无关。